MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results

Bulletin Express

03/12

Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.

The agenda includes: 1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025. 2. Authorising the publication of the FY2025 results. 3. Handling other routine corporate matters.

The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.

The current board comprises: • Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu. • Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin. • Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.

Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1165772728"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165772728\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165772728?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165772728","market":"us","top_or_hot":-1,"title":"MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results","media":"Bulletin Express","content":"<p>Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.</p>\n<p>The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.</p>\n<p>The current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.</p>\n<p>Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-12 16:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.</p>\n<p>The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.</p>\n<p>The current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.</p>\n<p>Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02181","symbol_name":"邁博藥業-B","start_time":0,"source_url":"","article_id":"1165772728","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165772728","pubTimestamp":1773305055,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026. The agenda includes:   1. Reviewing and approving the consolidated annual results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02181":"迈博药业-B"},"translate_title":"MABPHARM-B(02181)计划于2026年3月26日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02181":1},"content_text":"Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.\nThe agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.\nThe notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.\nThe current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.\nInvestors should note the forthcoming release of the FY2025 financial statements following the board meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}